Revance Therapeutics Inc (RVNC)

[iwfal]

RVNC

So MS is saying there’s a 30% chance the FDA rejects the Daxxify sBLA in cervical dystonia—even though the phase-3 trial in CD was unambiguously positive and there is no additional manufacturing or formulation development required for the new indication. Ludicrous!

The $22M and $39M figures (above) are just plain silly. Maybe MS does not realize that the Daxxify dose for CD is more than three times the dose for glabellar lines, which means each CD patient produces more than three times as much Daxxify revenue as each GL patient.

I spend a lot of time searching for these opportunities. Upstart company w much stronger product and plenty of cash where incumbents have tried to control perception via idiotic gaming of analysts. Qualcomm in late 90s was my first experience w this and I had reliable info from inside analyst community… so knew Nokia/Ericsson lying-to/pushing analysts. Incumbents sometimes fail to recognize when message control is obsolete and this provides opportunity.